Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin?

Neuroscience

Volumn 204, Issue , 2012, Pages 186-192

  Moreira, F A ^a   Aguiar, D C ^a   Terzian, A L B ^b,c   Guimaraes F S ^d   Wotjak, C T ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anandamide; Anxiety; Cannabinoid; Fear; Stress; Vanilloid

Indexed keywords

CANNABINOID 1 RECEPTOR; VANILLOID RECEPTOR 1;

ANXIETY; BEHAVIOR CHANGE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; GENE DELETION; HUMAN; LONG TERM POTENTIATION; NEUROANATOMY; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; ANXIETY; FEAR; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL; TRPV CATION CHANNELS;

EID: 84857133914     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.08.046     Document Type: Review

References (97)

1. Aguiar D.C., Terzian A.L., Guimarães F.S., Moreira F.A. Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. Psychopharmacology (Berl) 2009, 205:217-225.
2. Campos A.C., Guimarães F.S. Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1517-1521.
3. Canteras N.S., Resstel L.B., Bertoglio L.J., Carobrez Ade P., Guimarães F.S. Neuroanatomy of anxiety. Curr Top Behav Neurosci 2010, 2:77-96.
4. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
5. Cavanaugh D.J., Chesler A.T., Jackson A.C., Sigal Y.M., Yamanaka H., Grant R., O'Donnell D., Nicoll R.A., Shah N.M., Julius D., Basbaum A.I. Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. J Neurosci 2011, 31:5067-5077.
6. Chávez A.E., Chiu C.Q., Castillo P.E. TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci 2010, 13:1511-1518.
7. Chhatwal J.P., Davis M., Maguschak K.A., Ressler K.J. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005, 30:516-524.
8. Clapham D.E., Julius D., Montell C., Schultz G. International Union of Pharmacology. XLIX. Nomenclature and structure-function relationships of transient receptor potential channels. Pharmacol Rev 2005, 57:427-450.
9. Clapham D.E., Montell C., Schultz G., Julius D. International Union of Pharmacology. XLIII. Compendium of voltage-gated ion channels: transient receptor potential channels. Pharmacol Rev 2003, 55:591-596.
10. Corr P.J., McNaughton N. A two-dimensional neuropsychology of defense: fear/anxiety and defensive distance. Neurosci Biobehav Rev 2004, 28:285-305.
11. Cristino L., de Petrocellis L., Pryce G., Baker D., Guglielmotti V., Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006, 139:1405-1415.
12. Cristino L., Starowicz K., De Petrocellis L., Morishita J., Ueda N., Guglielmotti V., Di Marzo V. Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience 2008, 151:955-968.
13. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009, 259:413-431.
14. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34:605-613.
15. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
16. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat Rev Drug Discov 2008, 7:438-455.
17. Di Marzo V., Bisogno T., De Petrocellis L. Anandamide: some like it hot. Trends Pharmacol Sci 2001, 22:346-349.
18. Di Marzo V., Gobbi G., Szallasi A. Brain TRPV1: a depressing TR(i)P down memory lane?. Trends Pharmacol Sci 2008, 29:594-600.
19. Domenici M.R., Azad S.C., Marsicano G., Schierloh A., Wotjak C.T., Dodt H.U., Zieglgänsberger W., Lutz B., Rammes G. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 2006, 26:5794-5799.
20. Egertová M., Giang D.K., Cravatt B.F., Elphick M.R. A new perspective on cannabinoid signaling: complementary localization of fatty acid amide hydrolase and CB1 receptor in rat brain. Proc Biol Sci 1998, 265:2081-2085.
21. Gibson H.E., Edwards J.G., Page R.S., Van Hook M.J., Kauer J.A. TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 2008, 57:746-759.
22. Grueter B.A., Brasnjo G., Malenka R.C. Postsynaptic TRPV1 triggers cell type-specific long-term depression in the nucleus accumbens. Nat Neurosci 2010, 13:1519-1525.
23. Haller J., Bakos N., Szirmay M., Ledent C., Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002, 16:1395-1398.
24. Haller J., Mátyás F., Soproni K., Varga B., Barsy B., Németh B., Mikics E., Freund T.F., Hájos N. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 2007, 25:2445-2456.
25. Haller J., Varga B., Ledent C., Freund T.F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004, 15:299-304.
26. Häring M., Marsicano G., Lutz B., Monory K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 2007, 146:1212-1219.
27. Heifets B.D., Castillo P.E. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol 2009, 71:283-306.
28. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
29. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 1990, 87:1932-1936.
30. Hölter S.M., Kallnik M., Wurst W., Marsicano G., Lutz B., Wotjak C.T. Cannabinoid CB1 receptor is dispensable for memory extinction in an appetitively-motivated learning task. Eur J Pharmacol 2005, 510:69-74.
31. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
32. Hudson B.D., Hébert T.E., Kelly M.E. Ligand- and heterodimer-directed signaling of the CB1 cannabinoid receptor. Mol Pharmacol 2010, 77:1-9.
33. Jacob W., Yassouridis A., Marsicano G., Monory K., Lutz B., Wotjak C.T. Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes Brain Behav 2009, 8:685-698.
34. Kamprath K., Marsicano G., Tang J., Monory K., Bisogno T., Di Marzo V., Lutz B., Wotjak C.T. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci 2006, 26:6677-6686.
35. Kamprath K., Plendl W., Marsicano G., Deussing J.M., Wurst W., Lutz B., Wotjak C.T. Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling. Genes Brain Behav 2009, 8:203-211.
36. Kasckow J.W., Mulchahey J.J., Geracioti T.D. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:291-295.
37. Kathuria S., Gaetani S., Fegley D., Valiño F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003, 9:76-81.
38. Katona I., Sperlágh B., Sík A., Käfalvi A., Vizi E.S., Mackie K., Freund T.F. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999, 19:4544-4558.
39. Kawahara H., Drew G.M., Christie M.J., Vaughan C.W. Inhibition of fatty acid amide hydrolase unmasks CB(1) receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal gray. Br J Pharmacol 2011, 163:1214-1222.
40. Li D.P., Chen S.R., Pan H.L. VR1 receptor activation induces glutamate release and postsynaptic firing in the paraventricular nucleus. J Neurophysiol 2004, 92:1807-1816.
41. Lisboa S.F., Reis D.G., da Silva A.L., Corrêa F.M., Guimarães F.S., Resstel L.B. Cannabinoid CB1 receptors in the medial prefrontal cortex modulate the expression of contextual fear conditioning. Int J Neuropsychopharmacol 2010, 13:1163-1173.
42. Lisboa S.F., Resstel L.B., Aguiar D.C., Guimarães F.S. Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol 2008, 593:73-78.
43. Maccarrone M., Rossi S., Bari M., De Chiara V., Fezza F., Musella A., Gasperi V., Prosperetti C., Bernardi G., Finazzi-Agrò A., Cravatt B.F., Centonze D. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 2008, 11:152-159.
44. Maione S., Bisogno T., de Novellis V., Palazzo E., Cristino L., Valenti M., Petrosino S., Guglielmotti V., Rossi F., Di Marzo V. Elevation of endocannabinoid levels in the ventrolateral periaqueductal gray through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 2006, 316:969-982.
45. Maione S., Cristino L., Migliozzi A.L., Georgiou A.L., Starowicz K., Salt T.E., Di Marzo V. TRPV1 channels control synaptic plasticity in the developing superior colliculus. J Physiol 2009, 587:2221-2235.
46. Mallet C., Barrière D.A., Ermund A., Jönsson B.A., Eschalier A., Zygmunt P.M., Högestätt E.D. TRPV1 in brain is involved in acetaminophen-induced antinociception. PLoS One 2010, 5(9). pii: e12748.
47. Marsch R., Foeller E., Rammes G., Bunck M., Kössl M., Holsboer F., Zieglgänsberger W., Landgraf R., Lutz B., Wotjak C.T. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 2007, 27:832-939.
48. Marsicano G., Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999, 11:4213-4225.
49. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgänsberger W., Di Marzo V., Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
50. Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002, 159:379-387.
51. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
52. McGaraughty S., Chu K.L., Bitner R.S., Martino B., El Kouhen R., Han P., Nikkel A.L., Burgard E.C., Faltynek C.R., Jarvis M.F. Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM. J Neurophysiol 2003, 90:2702-2710.
53. McNaughton N., Gray J.A. Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. J Affect Disord 2000, 61:161-176.
54. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50:83-90.
55. Melis M., Pistis M., Perra S., Muntoni A.L., Pillolla G., Gessa G.L. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 2004, 24:53-62.
56. Mezey E., Tóth Z.E., Cortright D.N., Arzubi M.K., Krause J.E., Elde R., Guo A., Blumberg P.M., Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A 2000, 97:3655-3660.
57. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Drago F., Di Marzo V. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009, 34:593-606.
58. Millan M.J. The neurobiology and control of anxious states. Prog Neurobiol 2003, 70:83-244.
59. Monory K., Massa F., Egertová M., Eder M., Blaudzun H., Westenbroek R., Kelsch W., Jacob W., Marsch R., Ekker M., Long J., Rubenstein J.L., Goebbels S., Nave K.A., During M., Klugmann M., Wölfel B., Dodt H.U., Zieglgänsberger W., Wotjak C.T., Mackie K., Elphick M.R., Marsicano G., Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006, 51:455-466.
60. Moreira F.A., Aguiar D.C., Campos A.C., Lisboa S.F., Terzian A.L., Resstel L.B., Guimarães F.S. Antiaversive effects of cannabinoids: is the periaqueductal gray involved?. Neural Plast 2009, 2009:625469.
61. Moreira F.A., Aguiar D.C., Guimarães F.S. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 2007, 52:958-965.
62. Moreira F.A., Kaiser N., Monory K., Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008, 54:141-150.
63. Moreira F.A., Wotjak C.T. Cannabinoids and anxiety. Curr Top Behav Neurosci 2010, 2:429-450.
64. Naidu P.S., Varvel S.A., Ahn K., Cravatt B.F., Martin B.R., Lichtman A.H. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 2007, 192:61-70.
65. Niyuhire F., Varvel S.A., Thorpe A.J., Stokes R.J., Wiley J.L., Lichtman A.H. The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific. Psychopharmacology (Berl) 2007, 191:223-231.
66. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001, 29:729-738.
67. Owsianik G., Talavera K., Voets T., Nilius B. Permeation and selectivity of TRP channels. Annu Rev Physiol 2006, 68:685-717.
68. Pamplona F.A., Prediger R.D., Pandolfo P., Takahashi R.N. The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology 2006, 188:641-649.
69. Patel S., Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006, 318:304-311.
70. Patwardhan A.M., Jeske N.A., Price T.J., Gamper N., Akopian A.N., Hargreaves K.M. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A 2006, 103:11393-11398.
71. 2. Pharmacol Rev 2010, 62:588-631.
72. Plendl W., Wotjak C.T. Dissociation of within- and between-session extinction of conditioned fear. J Neurosci 2010, 30:4990-4998.
73. Premkumar L.S., Ahern G.P. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000, 408:985-990.
74. Resstel L.B., Moreira F.A., Guimarães F.S. Endocannabinoid system and fear conditioning. Vitam Horm 2009, 81:421-440.
75. Ross R.A. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003, 140:790-801.
76. Rubino T., Guidali C., Vigano D., Realini N., Valenti M., Massi P., Parolaro D. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 2008, 54:151-160.
77. Rubino T., Realini N., Castiglioni C., Guidali C., Viganó D., Marras E., Petrosino S., Perletti G., Maccarrone M., Di Marzo V., Parolaro D. Role in anxiety behaviour of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 2008, 18:1292-1301.
78. Santos C.J., Stern C.A., Bertoglio L.J. Attenuation of anxiety-related behaviour after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus. Behav Pharmacol 2008, 19:357-360.
79. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996, 16:4322-4334.
80. Sousa N., Almeida O.F., Wotjak C.T. A hitchhiker's guide to behavioral analysis in laboratory rodents. Genes Brain Behav 2006, 5(Suppl 2):5-24.
81. Starowicz K., Maione S., Cristino L., Palazzo E., Marabese I., Rossi F., de Novellis V., Di Marzo V. Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci 2007, 27:13739-13749.
82. Starowicz K., Nigam S., Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007, 114:13-33.
83. Takahashi K.A., Castillo P.E. The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience 2006, 139:795-802.
84. Terzian A.L., Aguiar D.C., Guimarães F.S., Moreira F.A. Modulation of anxiety-like behaviour by transient receptor potential vanilloid type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. Eur Neuropsychopharmacol 2009, 19:188-195.
85. Tóth A., Boczán J., Kedei N., Lizanecz E., Bagi Z., Papp Z., Edes I., Csiba L., Blumberg P.M. Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res 2005, 135:162-168.
86. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
87. van Der Stelt M., Di Marzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 2004, 271:1827-1834.
88. van der Stelt M., Trevisani M., Vellani V., De Petrocellis L., Schiano Moriello A., Campi B., McNaughton P., Geppetti P., Di Marzo V. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J 2005, 24:3026-3037.
89. Vaughan C.W., Connor M., Bagley E.E., Christie M.J. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 2000, 57:288-295.
90. Viveros M.P., Marco E.M., File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005, 81:331-342.
91. Vriens J., Appendino G., Nilius B. Pharmacology of vanilloid transient receptor potential calcium channels. Mol Pharmacol 2009, 75:1269-1279.
92. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410:588-592.
93. Wu L.J., Sweet T.B., Clapham D.E. International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol Rev 2010, 62:381-404.
94. Xing J., Li J. TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J Neurophysiol 2007, 97:503-511.
95. Zygmunt P.M., Chuang H., Movahed P., Julius D., Högestätt E.D. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 2000, 396:39-42.
96. Zygmunt P.M., Julius D., Di Marzo I., Högestätt E.D. Anandamide-the other side of the coin. Trends Pharmacol Sci 2000, 21:43-44.
97. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sørgård M., Di Marzo V., Julius D., Högestätt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400. 452-427.